EFICACITE ANTI-ANGINEUSE DU BEPRIDOL, INHIBITEUR CALCIQUE D'ACTION PROLONGEE: RESULTATS D'UNE ETUDE CONTROLEE CONTRE PLACEBO, MULTICENTRIQUE, DE 10 SEMAINES

Translated title of the contribution: Antianginal efficacy of bepridil, a long acting calcium channel blocker: Results of a 10 week, multicenter, placebo controlled study

J. S. Alpert, J. M. Gore, R. Dibianco

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Bepridil, a new slow channel blocking agent with a plasma half life of > 50 hours, was compared to placebo in 77 patients with chronic angina, each of whom had ≥ 3 anginal attacks/week and a positive treadmill exercise test characterized by pain and an ST segment change ≥0.1 mV. The effects on resting and maximal exercise hemodynamics, angina frequency and NTG tablet consumption were assessed during 5 sequential 2 week treatment phases (initial placebo, bepridil 200 mg, 30 mg and 400 mg per day followed by a final placebo phase). In addition, QD verses BID regimens were compared in double blind fashion. Bepridil (300 mg/day) reduced the angina frequency 61% (from 8,8 ± 10 (SD) to 3.4 ± 6 attacks/week, p <0.001) and NTG use 70% (p <0.001). Bepridil improved the exercise duration 25% (from 7.2 ± 2.4 to 9.0 ± 2.6 minutes, p <0.001) and the exercise work by 35% (p <0.001) without producing changes in heart rate or blood pressure. The efficacy of QD or BID administrations were similar. Bepridil (200 mg/day) produced less improvement than 300 mg/day; whereas 400 mg/day added few further benefits. No peripheral vascular, AV nodal or adverse inotropic or electrocardiographic effects were observed. A minority of patients reported tremor and/or minor GI disturbances. In this large group of patients with chronic angina, bepridil was found to be an effective and well tolerated antianginal agent when given once daily.

Translated title of the contributionAntianginal efficacy of bepridil, a long acting calcium channel blocker: Results of a 10 week, multicenter, placebo controlled study
Original languageFrench
Pages (from-to)1307-1311
Number of pages5
JournalRevue de Medecine
Volume24
Issue number28
StatePublished - Jan 1 1983
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antianginal efficacy of bepridil, a long acting calcium channel blocker: Results of a 10 week, multicenter, placebo controlled study'. Together they form a unique fingerprint.

  • Cite this